# Rapidly Progressive Glomerulonephritis with IgA Vasculitis

22

# Rapidly Progressive Glomerulonephritis with IgA Vasculitis

Early Recognition & Management of RPGN

⏱️ 60-75 min 🎯 Advanced Level 🔗 Multi-Module Integration

##  Integrated Learning Modules

This case integrates content from multiple lecture modules to provide comprehensive learning about RPGN

#### 🔬 Primary Module: Glomerular Disease

RPGN differential, pathophysiology, and management

#### 🔍 Supporting Module: Urinalysis

Dysmorphic RBCs and glomerular hematuria

#### 💊 Supporting Module: Immunosuppression

Steroid protocols and monitoring

#### 🩺 Supporting Module: Vasculitis

IgA vasculitis and systemic manifestations

#### Quick Access to Related Content:

[🔬 RPGN Overview](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html) [🔍 Dysmorphic RBCs](https://urinenephrology.org/2025_UDPA_Lectures_Live/urinalysis/dysmorphic-rbcs.html) [🩺 IgA Nephropathy](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html) [💊 Steroid Protocols](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/immunosuppression-protocols.html)

##  Pre-Case Assessment: Test Your Baseline Knowledge

Answer these questions before reviewing the case to assess your starting knowledge

1

#### Which of the following is the MOST specific urinary finding for glomerular hematuria?

A\) Red blood cell casts B) Dysmorphic red blood cells \>5% C) Proteinuria \>3 g/day D) Gross hematuria **Correct Answer: B**\
**Learning Point:** Acanthocytes and RBC casts support glomerular hematuria. More than 5% acanthocytes usually indicates a glomerular inflammatory source; this threshold does not apply to all dysmorphic cells. Neither sediment finding alone establishes the immune cause, and their absence does not exclude GN.\
**📚 Reference:** [Urinalysis Module: Dysmorphic RBCs](https://urinenephrology.org/2025_UDPA_Lectures_Live/urinalysis/dysmorphic-rbcs.html) 2

#### What defines rapidly progressive glomerulonephritis (RPGN)?

A\) Acute kidney injury developing over 24-48 hours B) Progressive loss of renal function over days to weeks with glomerular injury C) Chronic kidney disease with eGFR \<60 for \>3 months D) Nephrotic syndrome with rapid edema formation **Correct Answer: B**\
**Learning Point:** RPGN is a syndrome of rapidly worsening kidney function with suspected glomerular injury. Escalate immediately; a 50% GFR decline is not a waiting threshold. Evaluate hematuria, quantified proteinuria, sediment, serology, and biopsy as appropriate.\
**📚 Reference:** [Glomerular Disease Module: RPGN](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html) 3

#### In a patient on anticoagulation who needs tissue diagnosis for suspected glomerulonephritis, which alternative to kidney biopsy may be diagnostic?

A\) Bone marrow biopsy B) Skin biopsy of purpuric lesions C) Temporal artery biopsy D) Muscle biopsy **Correct Answer: B**\
**Learning Point:** Skin biopsy of purpuric or vasculitic lesions can show immunofluorescence patterns (IgA, IgG, C3) that correlate with renal pathology, particularly useful in IgA vasculitis/HSP and cryoglobulinemic vasculitis.\
**📚 Reference:** [Vasculitis Module: Diagnostic Approaches](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html)

##  Case Presentation

**Patient:** 75-year-old male farmer

**Chief Complaint:** "I've been peeing blood for the past 3 days, and I've got this rash on my legs"

**History of Present Illness:** Previously healthy farmer presents with 3-day history of gross hematuria and palpable purpura on lower extremities. Also reports mild abdominal pain, arthralgias in knees and ankles, and decreased urine output over past week. Denies recent URI, but had a "sore throat" about 2 weeks ago that resolved without treatment.

**Past Medical History:** Atrial fibrillation (on apixaban), hypertension, osteoarthritis

**Home Medications:** Apixaban 5 mg BID, lisinopril 20 mg daily, hydrochlorothiazide 25 mg daily

**Social History:** Retired farmer, still helps on family farm, non-smoker, occasional alcohol

### Physical Examination

- **Vital Signs:** BP 165/95, HR 88 (irregular), RR 18, T 37.2°C, O2 sat 96% RA
- **General:** Alert, mild distress, appears stated age
- **Skin:** Palpable purpura on bilateral lower extremities, non-blanching
- **HEENT:** No oral ulcers, mild pharyngeal erythema
- **Cardiovascular:** Irregular rhythm, no murmurs
- **Pulmonary:** Clear to auscultation bilaterally
- **Abdomen:** Soft, mild diffuse tenderness, no organomegaly
- **Extremities:** 1+ pitting edema bilaterally, purpuric rash as noted
- **Joints:** Mild swelling and tenderness of knees and ankles

#### 🚨 Critical Finding: Leukocytoclastic Vasculitic Rash

Palpable purpura with areas of confluence on bilateral lower extremities, characteristic of small vessel vasculitis. The distribution and appearance are classic for IgA vasculitis (formerly Henoch-Schönlein purpura).

### 🤔 Initial Clinical Reasoning Questions

4

#### Based on the presentation of palpable purpura, gross hematuria, abdominal pain, and arthralgia in this 75-year-old, what is the most likely diagnosis?

A\) Post-infectious glomerulonephritis B) IgA vasculitis (Henoch-Schönlein purpura) C) ANCA-associated vasculitis D) Cryoglobulinemic vasculitis **Correct Answer: B**\
**Clinical Reasoning:** The tetrad of palpable purpura, arthralgia, abdominal pain, and glomerulonephritis is classic for IgA vasculitis. While more common in children, it can occur in adults where it often has a more severe renal course.\
**📚 Reference:** [IgA Vasculitis Clinical Features](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html) 5

#### What is the most important immediate concern in this patient's management?

A\) Risk of gastrointestinal bleeding B) Risk of rapidly progressive glomerulonephritis C) Risk of intussusception D) Risk of thrombotic events **Correct Answer: B**\
**Clinical Reasoning:** Adult-onset IgA vasculitis has a higher risk of severe renal involvement and RPGN compared to pediatric cases. Early recognition and treatment are crucial to prevent irreversible kidney damage.\
**📚 Reference:** [RPGN Emergency Management](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html)

##  Laboratory Data & Analysis

### Initial Laboratory Values

| Parameter | Value | Normal Range | Clinical Significance |
|----|----|----|----|
| **Serum Creatinine** | 3.2 mg/dL | 0.7-1.3 mg/dL | Acute kidney injury |
| **Baseline Cr (1 month ago)** | 1.0 mg/dL | 0.7-1.3 mg/dL | Significant acute change |
| **BUN** | 78 mg/dL | 7-20 mg/dL | Azotemia |
| **Hemoglobin** | 10.8 g/dL | 14-18 g/dL | Mild anemia |
| **Platelets** | 245,000/μL | 150,000-400,000/μL | Normal (rules out TTP/HUS) |
| **C3 Complement** | 95 mg/dL | 90-180 mg/dL | Normal |
| **C4 Complement** | 28 mg/dL | 16-48 mg/dL | Normal |
| **ASO Titer** | 450 IU/mL | \<200 IU/mL | Elevated (red herring) |
| **ANCA** | Negative | Negative | Rules out ANCA vasculitis |
| **Anti-GBM** | Negative | Negative | Rules out anti-GBM disease |

### Urinalysis

| Parameter | Value | Clinical Significance |
|----|----|----|
| **Appearance** | Grossly bloody | Gross hematuria |
| **Protein** | 3+ (300 mg/dL) | Significant proteinuria |
| **Blood** | 4+ | Severe hematuria |
| **RBC** | TNTC/hpf | Glomerular bleeding |
| **RBC Morphology** | 80% dysmorphic RBCs (acanthocytes) | Diagnostic of glomerular hematuria |
| **RBC Casts** | 2-3/lpf | Confirms glomerular injury |
| **WBC** | 10-15/hpf | Mild pyuria |

#### 🔬 Critical Urinalysis Finding: Dysmorphic RBCs

The presence of 80% dysmorphic RBCs (especially acanthocytes with characteristic "Mickey Mouse ears" appearance) is highly specific for glomerular hematuria and strongly supports the diagnosis of glomerulonephritis. This finding, combined with RBC casts, strongly supports a glomerular source; clinical evaluation and tissue findings establish the disease mechanism.

### 📊 Laboratory Analysis Questions

6

#### The elevated ASO titer in this patient is significant because:

A\) It confirms post-streptococcal glomerulonephritis B) It indicates need for antibiotic therapy C) It is a red herring that doesn't change management D) It suggests rheumatic fever **Correct Answer: C**\
**Learning Point:** Elevated ASO titers can persist for months after streptococcal infection and may be incidentally elevated. In this case with normal complements, IgA vasculitis presentation, and skin biopsy showing IgA deposition, the ASO is a red herring. Post-streptococcal GN typically has low C3.\
**📚 Reference:** [Post-Infectious GN vs IgA Nephropathy](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html) 7

#### Why are the normal complement levels (C3 and C4) helpful in this case?

A\) They help narrow the differential to IgA nephropathy, ANCA vasculitis, or anti-GBM disease B) They rule out all forms of glomerulonephritis C) They indicate the disease is not severe D) They suggest the need for complement inhibitor therapy **Correct Answer: A**\
**Learning Point:** Normal complements rule out hypocomplementemic GN (post-infectious, lupus, cryoglobulinemia, C3 glomerulopathy). This narrows the RPGN differential to IgA nephropathy/vasculitis, ANCA vasculitis, and anti-GBM disease.\
**📚 Reference:** [Complement Patterns in GN](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html)

##  Diagnostic Approach & Tissue Diagnosis

#### ⚠️ Diagnostic Dilemma: Anticoagulation

**Challenge:** Patient on apixaban for atrial fibrillation, making kidney biopsy high-risk for bleeding complications.

**Options considered:**

- Hold anticoagulation for biopsy (risk of stroke)
- Bridge with heparin (still increased bleeding risk)
- Empiric treatment (miss potential diagnoses)
- **Alternative tissue diagnosis → Skin biopsy of purpuric lesions ✓**

### 🔬 Skin Biopsy Results

**Direct Immunofluorescence:**

- **IgA:** Strongly positive (3+) in vessel walls
- **C3:** Positive (2+) in vessel walls
- **IgG, IgM:** Negative
- **Fibrinogen:** Positive in vessel walls

**Light Microscopy:** Leukocytoclastic vasculitis with neutrophilic infiltration and nuclear debris

**Diagnosis:** IgA vasculitis (Henoch-Schönlein purpura) confirmed

### 🔍 Diagnostic Questions

8

#### In IgA vasculitis, skin biopsy immunofluorescence findings typically correlate with renal pathology. What would you expect to see on kidney biopsy?

A\) Linear IgG deposition along GBM B) Mesangial IgA and C3 deposition C) Granular IgG and C3 along capillary walls D) Absence of immune deposits (pauci-immune) **Correct Answer: B**\
**Learning Point:** IgA vasculitis shows identical immunofluorescence patterns in skin and kidney: predominant IgA deposition (with C3) in vessel walls (skin) and mesangium (kidney). This correlation allows skin biopsy to serve as a surrogate for renal biopsy when the latter is contraindicated.\
**📚 Reference:** [IgA Nephropathy Pathology](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html) 9

#### What percentage of adults with IgA vasculitis develop kidney involvement, and how does this compare to children?

A\) Adults 20%, Children 50% B) Adults 50%, Children 50% C) Adults 60-90%, Children 20-40% D) Adults 10%, Children 90% **Correct Answer: C**\
**Learning Point:** Adults with IgA vasculitis have higher rates of renal involvement (60-90%) compared to children (20-40%), and adult renal disease tends to be more severe with higher risk of progression to ESRD.\
**📚 Reference:** [Adult vs Pediatric IgA Vasculitis](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html)

##  Treatment & Management

### Initial Management Decision

Given the diagnosis of IgA vasculitis with RPGN (creatinine rising from 1.0 to 3.2 mg/dL), immediate immunosuppression is indicated.

#### Treatment Protocol Initiated:

- **Methylprednisolone** 500 mg IV daily × 3 days (pulse therapy)
- Followed by prednisone 1 mg/kg/day (75 mg daily)
- Continue apixaban (given high stroke risk)
- Hold ACE inhibitor temporarily (hyperkalemia risk)
- PPI for GI protection
- PJP prophylaxis with TMP-SMX

10

#### What is the primary rationale for using pulse methylprednisolone in this patient?

A\) It has fewer side effects than oral steroids B) Rapid anti-inflammatory effect for crescentic/RPGN C) Better for treating the skin manifestations D) Lower risk of infection **Correct Answer: B**\
**Treatment Rationale:** Pulse methylprednisolone provides rapid, high-intensity immunosuppression crucial for RPGN/crescentic GN. The goal is to quickly halt inflammatory injury and prevent irreversible glomerular scarring. Time is nephrons!\
**📚 Reference:** [Pulse Steroid Protocols in GN](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/index.html) 11

#### Which monitoring parameter is MOST important during the first 48 hours of pulse steroid therapy?

A\) White blood cell count B) Blood glucose and electrolytes C) Liver function tests D) Lipid panel **Correct Answer: B**\
**Monitoring Point:** High-dose steroids can cause significant hyperglycemia (even in non-diabetics), hypokalemia, and fluid retention. Monitor glucose q6h during pulse therapy and check electrolytes daily. Watch for steroid psychosis in elderly patients.\
**📚 Reference:** [Steroid Therapy Monitoring](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/index.html)

##  Clinical Course & Response to Treatment

### Treatment Timeline

| Day | Creatinine | Clinical Status | Management |
|----|----|----|----|
| **Day 1** | 3.2 mg/dL | Gross hematuria, oliguria | Started pulse steroids |
| **Day 2** | 3.6 mg/dL | Continued oliguria | Pulse steroid day 2 |
| **Day 3** | 4.0 mg/dL (peak) | Minimal urine output | Pulse steroid day 3, considered dialysis |
| **Day 4** | 3.8 mg/dL | Urine output improving | Started oral prednisone 75 mg |
| **Day 7** | 3.2 mg/dL | Hematuria resolving | Continue prednisone |
| **Day 14** | 2.4 mg/dL | Rash resolved, no hematuria | Prednisone 60 mg |
| **Day 30** | 1.8 mg/dL | Stable, proteinuria 500 mg/day | Prednisone taper begun |
| **Month 4** | 1.0 mg/dL (baseline) | Complete recovery, trace proteinuria | Prednisone 10 mg, continuing taper |

#### 💡 Clinical Pearl: Early Treatment Saves Kidneys

This case powerfully demonstrates that early recognition and treatment of RPGN can lead to COMPLETE renal recovery. Despite the creatinine peaking at 4.0 mg/dL (a level that often causes panic), prompt immunosuppression allowed full return to baseline function by month 4. This reinforces the critical teaching point: "Time is nephrons!" - delays of even days can mean the difference between complete recovery and dialysis dependence.

### 📈 Clinical Course Questions

12

#### What is the diagnostic accuracy of checking serum IgA levels for diagnosing IgA nephropathy?

A\) Elevated in 90% of cases - highly diagnostic B) Elevated in 50% of cases - moderately helpful C) Normal or elevated in most cases - not diagnostically useful D) Low levels rule out the diagnosis **Correct Answer: C**\
**Clinical Pearl:** Serum IgA levels are NOT diagnostically useful for IgA nephropathy. They can be normal, elevated, or occasionally low. The diagnosis requires demonstration of IgA deposition in kidney or skin tissue. Don't be misled by the disease name - checking serum IgA is a common mistake!\
**📚 Reference:** [IgA Nephropathy Diagnosis](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html) 13

#### This patient's complete recovery to baseline creatinine by month 4 demonstrates:

A\) The diagnosis was incorrect B) Early treatment prevented irreversible glomerular scarring C) IgA vasculitis never causes permanent damage D) Steroids should be continued indefinitely **Correct Answer: B**\
**Prognosis Point:** Complete recovery to baseline demonstrates that treatment was initiated before irreversible glomerular scarring occurred. This emphasizes the critical importance of early recognition and treatment of RPGN - "time is nephrons!" Delayed treatment often results in permanent kidney damage.\
**📚 Reference:** [RPGN Outcomes with Early Treatment](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html)

##  Understanding IgA Nephropathy: The 4-Hit Hypothesis & New Treatments

The 4-Hit Hypothesis: A Student's Guide to IgA Nephropathy Pathogenesis

IgA nephropathy develops through a sequential process of four "hits" that lead from abnormal antibody production to kidney damage. Understanding these steps helps explain why new drugs target specific points in this pathway.

#### 🎯 Hit 1: Abnormal IgA Production

**What happens:** The gut's immune system (Peyer's patches) produces defective IgA1 antibodies missing galactose sugars (Gd-IgA1)

**Why it matters:** These abnormal antibodies become "foreign" to the body

**Drug targets:** Tarpeyo (gut-targeted steroid), APRIL inhibitors

#### 🎯 Hit 2: Autoantibody Formation

**What happens:** The immune system makes antibodies against the abnormal IgA1

**Why it matters:** Creates an autoimmune response

**Drug targets:** B-cell depletion, BAFF/APRIL inhibitors

#### 🎯 Hit 3: Immune Complex Creation

**What happens:** The abnormal IgA1 and anti-IgA1 antibodies bind together forming large complexes

**Why it matters:** These complexes circulate and can deposit in kidneys

**Drug targets:** Complement inhibitors (iptacopan)

#### 🎯 Hit 4: Kidney Damage

**What happens:** Complexes deposit in kidney mesangium causing inflammation and scarring

**Why it matters:** Leads to proteinuria and kidney failure

**Drug targets:** Sparsentan, SGLT2 inhibitors

### 🔬 New FDA-Approved Therapies (2023-2025): A Revolution in Treatment

#### Three Game-Changing Approvals:

##### 1. Tarpeyo (Nefecon) - Targeted Gut Therapy

- **How it works:** Releases budesonide (steroid) specifically in the gut where abnormal IgA is made
- **Key benefit:** 27% proteinuria reduction, minimal systemic steroid effects
- **Student pearl:** Think "local treatment at the source" - like using a nasal spray for allergies instead of oral steroids

##### 2. Sparsentan (Filspari) - Dual Blockade

- **How it works:** Blocks both endothelin AND angiotensin receptors (two bad actors in kidney disease)
- **Key benefit:** approximately 49.8% within-arm proteinuria reduction from baseline at 36 weeks (PROTECT trial, Heerspink HJL et al. *Lancet* 2023;401:1584-94, PMID 37015244); between-arm vs irbesartan, sparsentan reduced UPCR by approximately 41% more (LSM ratio 0.59). Distinguish within-arm from between-arm reduction.
- **Student pearl:** Like blocking two exits instead of one - more effective than ARBs alone

##### 3. SGLT2 Inhibitors - Kidney Protection

- **How it works:** Originally diabetes drugs, now proven to protect kidneys regardless of diabetes
- **Key benefit:** 30% reduction in kidney function decline
- **Student pearl:** These drugs "rest" the kidney by reducing its workload - like putting an injured arm in a sling

##### 🚀 Coming Soon (In Trials):

- **APRIL inhibitors:** Target the very first hit - may prevent disease at its source
- **Complement inhibitors:** Block the inflammation cascade (Hit 3)
- **Combination therapy:** Using multiple drugs to target different hits simultaneously

### 📚 Test Your Understanding: 4-Hit Hypothesis & New Therapies

17

#### A patient asks why their new medication Tarpeyo (targeted-release budesonide) is better than regular prednisone for IgA nephropathy. Your best explanation would be:

A\) It's a stronger steroid that works better systemically B) It releases steroid directly in the gut where abnormal IgA is produced, with less systemic absorption C) It blocks complement activation in the kidney D) It's cheaper and easier to take than prednisone **Correct Answer: B**\
**Teaching Point:** Tarpeyo targets "Hit 1" by delivering budesonide directly to Peyer's patches in the gut where abnormal Gd-IgA1 is produced. About 90% is metabolized on first pass through the liver, minimizing systemic steroid side effects while treating the disease at its source.\
**📚 Reference:** [Targeted Therapies in IgAN](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html) 18

#### According to the 4-hit hypothesis, which "hit" would be most effectively prevented by APRIL inhibitors currently in clinical trials?

A\) Hit 1: Production of galactose-deficient IgA1 B) Hit 2: Formation of anti-Gd-IgA1 antibodies C) Hit 3: Immune complex formation D) Hit 4: Mesangial deposition and inflammation **Correct Answer: A**\
**Mechanism Insight:** APRIL (A Proliferation-Inducing Ligand) controls IgA class switching and production in gut-associated lymphoid tissue. Blocking APRIL prevents the initial production of abnormal Gd-IgA1, theoretically stopping the disease at its origin. Early trials show 50-60% proteinuria reduction!\
**📚 Reference:** [Future Therapies in IgAN](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html) 19

#### Why might combining drugs that target different "hits" be more effective than monotherapy in IgA nephropathy?

A\) It allows using lower doses of each drug B) It's more convenient for patients C) It interrupts the disease cascade at multiple points simultaneously D) It reduces the cost of treatment **Correct Answer: C**\
**Strategic Thinking:** Since IgA nephropathy involves a sequential cascade (4 hits), interrupting multiple steps simultaneously may provide synergistic benefit. For example, reducing abnormal IgA production (Hit 1) while also blocking kidney inflammation (Hit 4) addresses both upstream and downstream pathology. This is the future of IgAN treatment!\
**📚 Reference:** [Combination Strategies in IgAN](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html)

##  Learning Objectives Assessment

Evaluate your mastery of the key learning objectives from this case

#### 🎯 Learning Objective 1: Recognize RPGN as a Nephrology Emergency

14

#### A 65-year-old presents with creatinine rising from 1.2 to 2.8 mg/dL over 10 days with hematuria and proteinuria. What is the MOST appropriate initial step?

A\) Schedule outpatient nephrology follow-up in 2 weeks B) Start oral prednisone 60 mg daily C) Urgent nephrology consultation and expedited workup D) Repeat labs in 1 week **Correct Answer: C**\
**Emergency Recognition:** RPGN is a nephrology emergency requiring urgent evaluation and often same-day decisions about immunosuppression. Delays lead to irreversible kidney failure. Expedited serologies and tissue diagnosis (kidney or alternative) are crucial.\
**📚 Master This:** [RPGN Emergency Protocol](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/under-development.html)

#### 🎯 Learning Objective 2: Utilize Alternative Tissue Diagnosis When Kidney Biopsy is Contraindicated

15

#### Which clinical scenarios would make skin biopsy particularly useful for diagnosing glomerulonephritis?

A\) Any patient with chronic kidney disease B) Purpuric rash with suspected IgA vasculitis or cryoglobulinemia C) Isolated proteinuria without skin findings D) Diabetic nephropathy with foot ulcers **Correct Answer: B**\
**Diagnostic Strategy:** Skin biopsy with immunofluorescence can diagnose IgA vasculitis, cryoglobulinemic vasculitis, and sometimes lupus when purpuric/vasculitic lesions are present. The IF pattern correlates with renal pathology.\
**📚 Master This:** [Alternative Tissue Diagnosis in GN](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/index.html)

#### 🎯 Learning Objective 3: Understand Role of Dysmorphic RBCs in GN Diagnosis

16

#### A urinalysis shows 50-100 RBC/hpf. Which finding would most strongly suggest glomerular rather than urological source?

A\) Presence of bacteria B) Isomorphic RBCs with normal morphology C) \>20% acanthocytes (G1 cells) D) Terminal gross hematuria **Correct Answer: C**\
**Urinalysis Mastery:** Acanthocytes (ring forms with blebs) are highly specific for glomerular bleeding. \>5% dysmorphic RBCs or \>20% acanthocytes indicates glomerular source. Phase-contrast microscopy or special stains may be needed for visualization.\
**📚 Master This:** [RBC Morphology in Urinalysis](https://urinenephrology.org/2025_UDPA_Lectures_Live/urinalysis/rbc-morphology.html)

##  Advanced IgA Vasculitis & RPGN Integration

Test your mastery of IgA vasculitis pathophysiology and clinical decision-making

20

#### An adult patient with IgA vasculitis and RPGN achieves remission with steroids. Six months later, creatinine begins rising and proteinuria increases to 2 g/day. What is the MOST likely explanation?

A\) Steroid-induced nephrotoxicity B) Relapse of IgA vasculitis with ongoing mesangial IgA deposition C) Development of a new, unrelated glomerulonephritis D) Post-infectious glomerulonephritis from immunosuppression **Correct Answer: B**\
**Learning Point:** IgA vasculitis (and IgA nephropathy) has a significant relapse rate, particularly in adults. Unlike the pediatric form which is often self-limited, adult IgA vasculitis can have a chronic relapsing course with progressive renal damage from ongoing mesangial IgA deposition. Rising creatinine and proteinuria after initial remission should prompt repeat urinalysis for active sediment and consideration of repeat biopsy. Long-term monitoring with urinalysis and serum creatinine is essential, as some patients progress to ESRD despite initial treatment response.\
**📚 Reference:** [GN Module - IgA Nephropathy Prognosis](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/index.html) 21

#### Which feature MOST reliably distinguishes IgA vasculitis (Henoch-Schonlein purpura) from IgA nephropathy on clinical presentation?

A\) Presence of hematuria and proteinuria B) Normal complement levels C) Palpable purpura with systemic features (arthritis, abdominal pain, skin involvement) D) Mesangial IgA deposition on kidney biopsy **Correct Answer: C**\
**Learning Point:** IgA vasculitis and IgA nephropathy share the same renal pathology (mesangial IgA deposition) and are considered part of the same disease spectrum. The key distinguishing feature is the systemic manifestations in IgA vasculitis: palpable purpura (required for diagnosis), arthritis/arthralgias, abdominal pain (from GI vasculitis), and sometimes scrotal involvement. IgA nephropathy presents as isolated renal disease without these systemic features. Both have normal complement levels and both may show elevated serum IgA, so these features do not differentiate them.\
**📚 Reference:** [GN Module - IgA Vasculitis vs IgA Nephropathy](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/index.html)

##  Case Reflection & Multi-Module Integration

#### 🔬 Glomerular Disease Integration

- RPGN differential diagnosis approach
- Role of complement levels in narrowing differential
- IgA nephropathy pathophysiology
- Crescentic transformation of IgAN

[Review Complete Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/index.html)

#### 🔍 Urinalysis Integration

- Dysmorphic RBC identification
- Distinguishing glomerular from urological hematuria
- RBC cast significance
- Proteinuria quantification

[Review Urinalysis Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/urinalysis/index.html)

#### 💊 Immunosuppression Integration

- Pulse steroid protocols
- Monitoring during high-dose steroids
- Infection prophylaxis
- Steroid tapering strategies

[Review Immunosuppression Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/immunosuppression-protocols.html)

### 🎯 Key Integration Concepts

This case demonstrates the critical intersection of clinical pattern recognition, laboratory interpretation, and urgent management decision-making in RPGN. The integration of skin pathology findings with renal disease, the significance of urinary biomarkers like dysmorphic RBCs, and the time-sensitive nature of treatment initiation all highlight the importance of a systematic, multi-disciplinary approach to rapidly progressive glomerulonephritis.

Key takeaway: **"Time is nephrons"** - early recognition and treatment of RPGN can mean the difference between renal recovery and dialysis dependence.

## 📝 Case Summary & Clinical Pearls

This case of a 75-year-old farmer with IgA vasculitis presenting as RPGN illustrates several critical concepts in nephrology. The combination of palpable purpura, gross hematuria with dysmorphic RBCs, and rapidly rising creatinine demanded urgent intervention. The use of skin biopsy as an alternative to kidney biopsy in an anticoagulated patient proved diagnostic, showing IgA deposition consistent with IgA vasculitis. Early treatment with pulse steroids led to complete renal recovery with return to baseline creatinine by month 4, powerfully demonstrating that prompt recognition and treatment can prevent permanent kidney damage.

### 🔑 Key Clinical Pearls from This Case:

- **RPGN is a nephrology emergency:** Rapid evaluation and treatment within days can prevent dialysis dependence
- **Dysmorphic RBCs are diagnostic gold:** Acanthocytes \>5% of urinary RBCs usually indicate a glomerular inflammatory source; interpret sediment with proteinuria and the clinical course
- **Skin can substitute for kidney:** In IgA vasculitis and cryoglobulinemia, skin biopsy IF correlates with renal pathology
- **Normal complements narrow the differential:** Points toward IgA nephropathy, ANCA vasculitis, or anti-GBM disease
- **Don't be fooled by red herrings:** Elevated ASO doesn't always mean post-streptococcal GN - consider the whole clinical picture
- **Adult IgA vasculitis is more severe:** Higher rates of renal involvement and worse prognosis than pediatric cases
- **Early steroids save nephrons:** This case proves it - complete recovery from Cr 4.0 to baseline 1.0 with prompt treatment
- **Don't check serum IgA levels:** Common mistake - they're normal in most cases and not diagnostically useful

#### 🎓 Ready for the Next Challenge?

[← Previous: RPGN & Dialysis](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case21_rpgn_dialysis.html) [→ Next: Cardiorenal Syndrome](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case23_enhanced.html) [📋 All Cases](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/index.html)

## 📚 References

1.  **Trimarchi H, Barratt J, Cattran DC, et al.** Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. *Kidney Int* 2017;91(5):1014-1021. PMID: 28341274. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28341274/) *— current MEST-C scoring framework (Mesangial hypercellularity, Endocapillary hypercellularity, Segmental sclerosis, Tubular atrophy/interstitial fibrosis, Crescents). Anchor for the kidney biopsy interpretation in IgA-vasculitis nephritis (renal pathology mirrors IgA nephropathy).*
2.  **Rovin BH, Adler SG, Barratt J, et al.** KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int* 2021;100(4S):S1-S276. PMID: 34556256. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34556256/) *— current consensus framework for IgA nephropathy and IgA vasculitis nephritis: maximally tolerated RAAS inhibition, supportive care first; immunosuppression for high-risk progressive disease or RPGN. Anchor for management algorithm.*
3.  **Barratt J, Lafayette R, Kristensen J, et al.** Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. *Kidney Int* 2023;103(2):391-402. PMID: 36270561. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36270561/) *— NefIgArd Part A. Targeted-release budesonide (Nefecon) reduced UPCR by 27% vs placebo and preserved eGFR by 3.87 mL/min/1.73m². Modern non-systemic immunomodulation option for IgA nephropathy.*
4.  **Heerspink HJL, Radhakrishnan J, Alpers CE, et al.** Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet* 2023;401(10388):1584-1594. PMID: 37015244. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37015244/) *— PROTECT trial. Dual ET-A and AT1 receptor antagonist sparsentan reduced UPCR 41% more than irbesartan in IgA nephropathy at 36 weeks. Modern dual-RAAS-ET option referenced in the supportive care discussion.*
5.  **Audemard-Verger A, Pillebout E, Guillevin L, Thervet E, Terrier B.** IgA vasculitis (Henoch-Shönlein purpura) in adults: Diagnostic and therapeutic aspects. *Autoimmun Rev* 2015;14(7):579-85. PMID: 25688001. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25688001/) *— review of adult IgA vasculitis: more severe renal course than pediatric (60-90% vs 20-40% renal involvement), higher ESRD risk. Anchor for Q9 adult-vs-pediatric teaching.*
6.  **Lv J, Zhang H, Wong MG, et al.** Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. *JAMA* 2017;318(5):432-442. PMID: 28763548. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28763548/) *— TESTING trial. Initial study halted early for safety with high-dose methylprednisolone in IgAN; modern reduced-dose results inform Q10 pulse-steroid teaching for crescentic disease vs proteinuric IgAN.*
7.  **Pillebout E, Verine J, Demouchy C, et al.** Successful outcome using rituximab as the only immunomodulation in Henoch-Schönlein purpura: case report. *Nephrol Dial Transplant* 2011;26(6):2044-6. PMID: 21436378. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21436378/) *— supports the rituximab consideration for refractory adult IgA vasculitis (off-label, extrapolated from IgAN/AAV experience). Anchor for advanced therapy discussion.*
8.  **Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S.** Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. *BMJ* 2013;346:e8525. PMID: 23299844. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23299844/) *— "triple whammy" prerenal AKI mechanism — relevant background for managing concurrent RAAS-blockade with iodinated contrast / NSAIDs in this acutely declining patient.*

📚 For Educational Purposes Only - Case-Based Learning Module

© 2025 Andrew Bland MD - All Rights Reserved

### Also on this topic

The same subject at other levels of depth.

- **Lecture:** [ANCA Vasculitis \&amp; Rapidly Progressive Glomerulonephritis](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/rpgn-anca-vasculitis.html)


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case22_rpgn_iga.html) · Markdown synchronized October 3, 2026.